Unibest

Pharmaceutical intermediates

Palbociclib Intermediates

7 pharmaceutical intermediates for Palbociclib. Indication: Breast Neoplasma.

提交项目All intermediates

About Palbociclib

Originator
Pfizer Inc
Indication
Breast Neoplasma
Approved Date
02/03/2015
DS/DP
03/05/2027

Available intermediates

7 intermediates currently listed for Palbociclib. Request specifications, documentation or a quotation for any item below.

Palbociclib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine733039-20-8//
2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one1013916-37-4//
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one1016636-76-2//
tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate571188-59-5//
Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate571189-16-7//
tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate866084-31-3//
PD 0332991 HCl827022-32-2//

Other programs under P

PacritinibParecoxib sodiumParicalcitolPaxlovidPazopanib HydrochloridePeficitinib HydrobromidePemafibratePeramivir

Building toward Palbociclib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →